product name Ondansetron HCl
Description: Ondansetron HCl (also known as GR 38032F, GR-C507/75) is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy. The 5-HT3A receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 microM) signal by 70% and at 3 nM it abolished the response. Acute ondansetron administration at the lowest dose (0.1 mg/kg, IP) tested had no effect, while other doses (0.33 and 1 mg/kg, IP) produced improvements in auditory gating.
References: Behav Brain Res. 2011 Mar 17;218(1):121-8; Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):908-16.
329.82
Formula
C18H19N3O.HCl
CAS No.
99614-01-4
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 66 mg/mL (200.1 mM)
Water: 24 mg/mL (72.8 mM)
Ethanol: 10 mg/mL (30.3 mM)
Solubility (In vivo)
Synonyms
GR 38032F
other peoduct :
| In Vitro |
In vitro activity: Ondansetron decreases the intensity of withdrawal signs such as increased defecation, jumping and wet-dog shakes, elevated the nociceptive threshold values which are decreased by precipitated withdrawal, but produces no change in urination, rectal temperature or salivation. Ondansetron and granisetron significantly enhances gastric emptying of glass beads and improves cisplatin-induced slowing of gastric emptying in rats. Ondansetron exhibits a biphasic dose-response profile in mice, with antidepressant-like effects peaking at 0.1 mg/kg, in the forced swim and tail suspension tests. Ondansetron pretreatment augments the antidepressant effects of fluoxetine and venlafaxine but does not influence the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron (10 mg/kg) reverses hyperactivity in the open field, and decreases the percentage entry and time spent in open arms in the elevated plus maze. Ondansetron, a selective and potent 5HT3 receptor antagonist, is shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. Ondansetron is able to attenuate increases in dopamine activity, produces pharmacologically with amphetamine without affecting baseline dopamine activity. Ondansetron facilitates performance in young adult and aged animals, and inhibits an impairment in habituation induced by scopolamine, electrolesions or ibotenic acid lesions of the nucleus basalis magnocellularis. Ondansetron and arecoline antagonizes a scopolamine-induced impairment. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 1997 Dec 11;340(2-3):111-9; Jpn J Pharmacol. 1995 Nov;69(3):205-14. |
